Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 11/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30564376 | 0.82 | GPR35 (0.41) | GPR35ALDH1A1HPGDTSHRKDM4E | |
| SCHEMBL2727696 | 0.82 | GPR35 (0.66) | GPR35ALDH1A1HPGDTSHRPTPN1 | |
| SCHEMBL476351 | 0.79 | GPR35 (0.67) | GPR35TSHRPTPN1DAO | |
| SCHEMBL7233575 | 0.78 | GPR35 (0.52) | GPR35ALDH1A1HPGDTSHRPTPN1 | |
| SCHEMBL9826280 | 0.78 | GPR35 (0.52) | GPR35ALDH1A1HPGDTSHRPTPN1 | |
| SCHEMBL31398791 | 0.77 | GPR35 (0.38) | GPR35MEN1KMT2A | |
| SCHEMBL9825814 | 0.77 | MAPT (0.50) | GPR35ALDH1A1HPGDTSHRKDM4E | |
| SCHEMBL1760858 | 0.75 | GPR35 (0.49) | GPR35ALDH1A1HPGDPTPN1 | |
| SCHEMBL731095 | 0.72 | GPR35 (0.50) | GPR35ALDH1A1HPGDTSHRKDM4E | |
| SCHEMBL9370925 | 0.71 | GPR35 (0.48) | GPR35ALDH1A1HPGDTSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308662-B2 | Thienopyranones as kinase and epigenetic inhibitors | Signal Rx Pharmaceuticals., Inc. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170334925-A1 | Thienopyranones as Kinase and Epigenetic Inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170101418-A1 | Thienopyranones as Kinase and Epigenetic Inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2017-04-13 | — | — | US | disclosed |
| US-9505780-B2 | Thienopyranones as kinase and epigenetic inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150344494-A1 | Thienopyranones as Kinase and Epigenetic Inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| EP-1697354-B1 | ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-1745032-B1 | CXCR1 and CXCR2 chemokine antagonists | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-7947720-B2 | 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-05-24 | — | — | US | disclosed |
| WO-2004033440-A1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040034229-A1 | 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists | SCHERING CORPORATION | 2004-02-19 | — | — | US | disclosed |
| EP-1381590-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | Schering Corporation (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030204085-A1 | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | PHARMACOPEIA, INC. | 2003-10-30 | — | — | US | disclosed |
| EP-1355875-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030097004-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists | SCHERING CORPORATION | 2003-05-22 | — | — | US | disclosed |
| WO-2003031440-A1 | 3,4-DI-SUBSTITUTED MALEIMIDE COMPOUNDS AS CXC-CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2002083624-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002076926-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| WO-2000064904-A1 | 5,7-BICYCLIC AMIDINE DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | CCR1, ACKR3, CXCR1 | GPR35 144/4885ALDH1A1 1019/4885HPGD 200/4885 |
| US-20170101418-A1 | Thienopyranones as Kinase and Epigenetic Inhibitors | MYC, BRD4, MKNK1 | GPR35 4593/4885ALDH1A1 3334/4885HPGD 3347/4885 |
| US-20040034229-A1 | 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists | CXCR1, CCR1, CCL2 | GPR35 270/4885ALDH1A1 704/4885HPGD 404/4885 |
| US-20170334925-A1 | Thienopyranones as Kinase and Epigenetic Inhibitors | MYC, BRD4, MYCBP | GPR35 4506/4885ALDH1A1 3116/4885HPGD 3244/4885 |
| US-20030097004-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists | CCR1, ACKR3, CXCR1 | GPR35 146/4885ALDH1A1 797/4885HPGD 123/4885 |
| US-20030204085-A1 | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | CCR1, CXCR1, ACKR3 | GPR35 147/4885ALDH1A1 854/4885HPGD 154/4885 |
| US-10308662-B2 | Thienopyranones as kinase and epigenetic inhibitors | MYC, BRD4, MYCBP | GPR35 4506/4885ALDH1A1 3116/4885HPGD 3244/4885 |
| US-20150344494-A1 | Thienopyranones as Kinase and Epigenetic Inhibitors | MYC, BRD4, MKNK1 | GPR35 4572/4885ALDH1A1 3059/4885HPGD 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.